American Century Companies Inc. Has $253.70 Million Stake in IQVIA Holdings Inc. $IQV

Key Points

• American Century Companies Inc. increased its stake in IQVIA Holdings by 26.8% to approximately $253.7 million, owning 1,438,995 shares after acquiring 304,258 additional shares in the first quarter.
• Several analysts raised their price targets for IQVIA, with Truist Financial setting a target of $235 and UBS Group at $225, while the stock carries a consensus rating of Moderate Buy.
• IQVIA reported a quarterly earnings per share of $2.81, exceeding analysts' expectations, with total revenue of $4.02 billion, marking a 5.3% increase from the same quarter last year.

American Century Companies Inc. increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 26.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,438,995 shares of the medical research company's stock after purchasing an additional 304,258 shares during the period. American Century Companies Inc. owned approximately 0.83% of IQVIA worth $253,695,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. American National Bank & Trust acquired a new position in IQVIA in the first quarter valued at about $26,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA in the first quarter valued at approximately $33,000. Finally, ST Germain D J Co. Inc. raised its stake in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Robert W. Baird upped their price objective on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Mizuho upped their price objective on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Truist Financial upped their price objective on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. decreased their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Finally, Cowen reaffirmed a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $228.62.

IQVIA Price Performance

Shares of NYSE IQV traded up $0.0970 during mid-day trading on Tuesday, hitting $192.6370. 1,093,641 shares of the stock traded hands, compared to its average volume of 1,979,047. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The company has a market cap of $32.75 billion, a PE ratio of 27.88, a price-to-earnings-growth ratio of 2.10 and a beta of 1.30. The firm has a 50 day simple moving average of $171.16 and a two-hundred day simple moving average of $168.34.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.IQVIA's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Activity

In other news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.